[Informational value of bone scintigraphy in primary bone tumors (proceedings)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W Keyl.
Explore the source record for details and available documents.
126 osteosarcoma under the age of 15 years are followed up in an interclinical study. There is a steady increase of tumor incidence towards the 15th year with a slight male preponderance. The main sites of the tumor are the distal femur followed by the proximal tibia and humerus. Evidence of multiple metastases is most often present in the lungs, less often in the skeleton. Nearly always metastases became evident within 2 1/2 years after diagnosis (98%). Therefore the 2 1/2-year disease--free survival rate seems to be sufficient for prognostic evaluation. The over all 2 1/2-year survival rate was 17,5%. Though the different methods of treatment are not statistically valid, the best results can be expected after early amputation. By radiotherapy alone no cure has been achieved. Survivals were seen at any age and at any site of long bones (distal femur, proximal tibia, humerus, femur, distal radius). Prognosis of osteosarcoma in the childhood is similar to that of the adult group.
Comparative studies between radiological (equals R; x-ray, thermography, angiography) and nuclear medical examinations (equals NM; scanner-, scintillation camera-sequential scintigraphy) in 339 patients with different bone diseases led to the following results: Thermography proved to be inferior to scanning in detecting of bone diseases. Angiography was the procedure of choice in detecting malignant bone tumors. Sequential scintigraphy performed by means of the Anger-HP-scintillation camera and Intertechnique-Cine-System allowed to establish the kinetic behaviour of tumors: an early increased TcPoP accumulation was observed in tumors with high perfusion (sarcoma), a late accumulation in those with low perfusion (osteoid osteoma).
Using the infrared-thermography a exact picture of the body surface can be obtained. Injuries are recognized by a local hyperthermy, if the impaired structures do not lie too deep under the body surface. In combination with anamnesis and clinical and radiological examination the infrared-thermography plays an important role in the diagnosis, management and control of therapy. The results of examinations of 82 patients with distorsions, ruptures of tendons or ligaments, injuries of the meniscus and tendo- and chondropathias as well as of 50 athletes are described. In all cases a hyperthermy was found in the area of injury. In those cases, in which an injury was not the cause of the hyperthermy, other processes could be found (furunculosis, phlebitis, tumor).
A study is presented of the aetiology and results of treatment in a group of 125 proven osteosarcomas present in children under fifteen years of age. These cases have been collected from the records of one English and six European treatment centres. There is a slight male preponderance, but the striking aetiological feature is the very high proportion of tumours of the long bones of the limbs (96 per cent). The two and a half and five year disease-free survival rates were respectively 15 and 12 per cent, with a further 9 per cent still living, but under observation for less than two and a half years. Evidence of metastasis after two and a half years is very unusual, but no child with a tumour of an axial or girdle bone lived this length of time. Although the differences in the results of the different methods of treatment employed are not statistically valid, the largest number of long survivors had been treated by early amputation, which method also provided the lowest rate of local tumour recurrences. Reasons are discussed which indicate that prompt ablation is the treatment of choice, perhaps with certain advantages in the light of recent advances in adjuvant treatment. The past situation in connection with childhood osteosarcoma certainly provides strong support for immediate carefully designed clinical trials of the new adjuvant methods cited.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.